Tuberculosis pharmacotherapy: strategies to optimize patient care

Bibliography

• American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62
   PubMed Web of Science ®Google Scholar
• Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3(10 Suppl 2):S231-79
   PubMed Web of Science ®Google Scholar
• Peloquin CA. Clinical pharmacology of the anti-tuberculosis drugs. Third editon. In: Davies PDO, editor, Clinical Tuberculosis. London: Arnold, 2003. p. 171-90
   Google Scholar
• Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007;4(12):e344
   PubMed Web of Science ®Google Scholar
• Lenaerts AJ, Hoff D, Aly S, et al. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by R207910. Antimicrob Agents Chemother 2007;51:3338-45
   PubMed Web of Science ®Google Scholar
• Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003;167:1348-54
   PubMed Web of Science ®Google Scholar
• Aquinas M. Short-course therapy for tuberculosis. Drugs 1982;24:118-32
   PubMed Web of Science ®Google Scholar
• Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985;66:219-25
   PubMedGoogle Scholar
• Mitchison DA, Coates AR. Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs. Curr Pharm Design 2004;10:3285-95
   PubMed Web of Science ®Google Scholar
• Davies GR, Khoo SH, Aarons LJ. Optimal sampling strategies for early pharmacodynamic measures in tuberculosis. J Antimicrob Chemother 2006;58:594-600
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Vernon A. Antimycobacterial agents: rifamycins for mycobacterial infections. Second edition. In: Yu VL, Edwards G, McKinnon PS, et al., editors. Antimicrobial Chemotherapy and Vaccines. Vol. 2. Antimicrobial Agents. Pittsburgh, PA: ESun Technologies, 2005. p. 383-402
   Google Scholar
• Heifets LB. Antimycobacterial drugs. Sem Respir Infect 1994;9:84-103
   PubMedGoogle Scholar
• Hobby GL. Summation of experimental studies on the action of rifampin. Chest 1972;61:550-4
   PubMed Web of Science ®Google Scholar
• Verbist L. Mode of action of antituberculous drugs (Part I). Medicon Intl 1974;3:11-23
   Google Scholar
• Verbist L. Mode of action of antituberculous drugs (Part II). Medicon Intl 1974;3:3-17
   Google Scholar
• Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Resp Res 2001;2:164-8
   PubMed Web of Science ®Google Scholar
• Blanchard JS. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu Rev Biochem 1996;65:215-39
   PubMed Web of Science ®Google Scholar
• Trnka L, Mison P, Bartmann K, Otten H. Experimental evaluation of efficacy. In: Bartmann K, editor. Antituberculosis Drugs. Berlin: Springer-Verlag, 1988. p. 31-232
   Google Scholar
• Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;51:3781-8
   PubMed Web of Science ®Google Scholar
• Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981;123:367-71
   PubMed Web of Science ®Google Scholar
• Verbist L, Gyselen A. Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am Rev Respir Dis 1968;98(6):923-32
   PubMed Web of Science ®Google Scholar
• Dickinson JM, Mitchison DA. Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle 1970;51:82-94
   PubMedGoogle Scholar
• Verbist L. Rifampicin activity ‘in vitro’ and in established tuberculosis in mice. Acta Tuberc Pneumol Belg 1969;60:397-412
   PubMedGoogle Scholar
• Nuermberger E, Rosenthal I, Zhang M, et al. Does autoinduction of rifamycin metabolism affect the efficacy of TB chemotherapy? Proceedings of the American Thoracic Society International Conference. San Francisco, CA, USA 18-23 May 2007:A971
   Google Scholar
• Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47:2118-24
   PubMed Web of Science ®Google Scholar
• Ruslami R, Nijland HM, Alisjahbana B, et al. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 2007;51:2546-51
   PubMed Web of Science ®Google Scholar
• Sirgel FA, Fourie PB, Donald PR, et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005;172:128-35
   PubMed Web of Science ®Google Scholar
• Diacon AH, Patientia RF, Venter A, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007;51:2994-6
   PubMed Web of Science ®Google Scholar
• Decroix G, Kreis B, Sors C, et al. Comparison between regimes of rifampicin-isoniazid administered daily and administered twice a week (initial results of a comparative study conducted in 4 medical services of the Parisian region). Rev Tuberc Pneumol 1969;33:751-68
   PubMedGoogle Scholar
• Kreis B, Pretet S, Birenbaum J, et al. Two three-month treatment regimens for pulmonary TB. Bull Int Un Tuberc 1976;51:71-5
   PubMedGoogle Scholar
• Long MW, Snider DE Jr, Farer LS. US Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119:879-94
   PubMed Web of Science ®Google Scholar
• East African/British Medical Research Council. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972;1:1079-85
   PubMed Web of Science ®Google Scholar
• Verbist L, Rollier F. Pharmacological study of rifampicin after repeated high dosage during intermittent combined therapy. II. Bilirubin levels and other biochemical determinations. Respir Int Rev Thorac Dis 1971;28(Suppl):17-28
   Google Scholar
• Decroix G, Kreis B, Sors C, et al. Comparative study of the treatment of pulmonary tuberculosis by a combination of rifampicin and isoniazid administered daily and twice weekly for a year. Rev Tuberc Pneumol 1971;35:39-54
   PubMedGoogle Scholar
• A comparative study of daily followed by twice or once weekly regimens of ethambutol and rifampicin in retreatment of patients with pulmonary tuberculosis. The results at 1 year. A cooperative tuberculosis chemotherapy study in Poland. Tubercle 1975;56:1-26
   PubMedGoogle Scholar
• A comparative study of daily followed by twice or once weekly regimens of ethambutol and rifampicin in retreatment of patients with pulmonary tuberculosis: second report. A cooperative tuberculosis chemotherapy study in Poland. Tubercle 1976;57:105-13
   PubMedGoogle Scholar
• Hong Kong Tuberculosis Treatment Services, Brompton Hospital, British Medical Research Council. A controlled trial of daily and intermittent rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis: results up to 30 months. Tubercle 1975;56:179-89
   PubMedGoogle Scholar
• Dutt AK, Moers D, Stead WW. Undesirable side effects of isoniazid and rifampin in largely twice-weekly short-course chemotherapy for tuberculosis. Am Rev Respir Dis 1983;128:419-24
   PubMed Web of Science ®Google Scholar
• Poole G, Stradling P, Worlledge S. Potentially serious side effects of high-dose twice-weekly rifampicin. Brit Med J 1971;3(5770):343-7
   PubMed Web of Science ®Google Scholar
• Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British Medical Research Council Study. Am Rev Respir Dis 1976;114:471-5
   PubMedGoogle Scholar
• Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. Tubercle 1979;60:201-10
   PubMedGoogle Scholar
• Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-52
   PubMed Web of Science ®Google Scholar
• McEvoy GK, Snow EK, Kester L, editors. AHFS Drug Information 2006. Bethesda, MD: American Society of Health-System Pharmacists, 2006
   Google Scholar
• Peloquin CA. Antituberculosis drugs: pharmacokinetics. In: Heifets LB, editor, Drug-Susceptibility in the Chemotherapy of Mycobacterial Infections. Boca Raton, FL: CRC Press, 1991. p. 89-122
   Google Scholar
• Girling DJ. Adverse effects of antituberculosis drugs. Drugs 1982;23:56-74
   PubMed Web of Science ®Google Scholar
• Pande JN, Singh SP, Khilnani GC, et al. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996;51:132-6
   PubMed Web of Science ®Google Scholar
• Sarma GR, Immanuel C, Kailasam S, et al. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 1986;133:1072-5
   PubMed Web of Science ®Google Scholar
• Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991;99:465-71
   PubMed Web of Science ®Google Scholar
• Girling DJ. Adverse reactions to rifampicin in antituberculosis regimens. J Antimicrob Chemother 1977;3:115-32
   PubMed Web of Science ®Google Scholar
• Martinez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine 1999;78:361-9
   PubMed Web of Science ®Google Scholar
• Aquinas M, Allan WG, Horsfall PA, et al. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Brit Med J 1972;1(5803):765-71
   PubMed Web of Science ®Google Scholar
• Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983;5(Suppl 3):S440-50
   PubMedGoogle Scholar
• Peloquin C. What is the ‘right’ dose of rifampin? Int J Tuberc Lung Dis 2003;7:3-5
   PubMed Web of Science ®Google Scholar
• Mitchison DA. Antimicrobial therapy of tuberculosis: justification for currently recommended treatment regimens. Semin Respir Crit Care Med 2004;25:307-15
   PubMed Web of Science ®Google Scholar
• Boman G, Ringberger VA. Binding of rifampicin by human plasma proteins. Eur J Clin Pharmacol 1974;7:369-73
   PubMed Web of Science ®Google Scholar
• Mehta JB, Shantaveerapa H, Byrd RP, et al. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001;120:1520-4
   PubMed Web of Science ®Google Scholar
• Kimerling ME, Phillips P, Patterson P, et al. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998;113:1178-83
   PubMed Web of Science ®Google Scholar
• Humber DP, Nsanzumuhire H, Aluoch JA, et al. Controlled double-blind study of the effect of rifampin on humoral and cellular immune responses in patients with pulmonary tuberculosis and in tuberculosis contacts. Am Rev Respir Dis 1980;122:425-36
   PubMedGoogle Scholar
• Dhar S, Kaur I, Sharma VK, Kumar B. ‘Flu’ syndrome due to rifampin; experience with four cases. Int J Lepr Other Mycobact Dis 1995;63:92-4
   PubMedGoogle Scholar
• Bertrand A. Antibiotic treatment of brucellosis. Presse Med 1994;23:1128-31
   PubMed Web of Science ®Google Scholar
• Reichler MR, Allphin AA, Breiman RF, et al. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio. J Infect Dis 1992;166:1346-53
   PubMed Web of Science ®Google Scholar
• Drancourt M, Stein A, Argenson JN, et al. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997;39:235-40
   PubMed Web of Science ®Google Scholar
• Baty V, Hoen B, Schuhmacher H, et al. Legionella jordanis pneumonia unresponsive to fluoroquinolones in a non-immunocompromised host. Scand J Infect Dis 1997;29:319-20
   PubMed Web of Science ®Google Scholar
• Kochar DK, Aseri S, Sharma BV, et al. The role of rifampicin in the management of cutaneous leishmaniasis. QJM 2000;93:733-7
   PubMedGoogle Scholar
• Namdar R, Ebert SC, Peloquin CA. Drugs for tuberculosis. Second edition. In: Piscitelli SC, Rodvold KA, editors. Drug Interactions in Infectious Diseases, Totowa, NJ: Humana Press, 2006. p. 191-214
   Google Scholar
• Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis 1999;28:419-29; quiz 30
   PubMed Web of Science ®Google Scholar
• Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327-41
   PubMed Web of Science ®Google Scholar
• Grange JM, Winstanley PA, Davies PD. Clinically significant drug interactions with antituberculosis agents. Drug Saf 1994;11:242-51
   PubMed Web of Science ®Google Scholar
• Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf 2002;25:111-33
   PubMed Web of Science ®Google Scholar
• Israili ZH, Rogers CM, el-Attar H. Pharmacokinetics of antituberculosis drugs in patients. J Clin Pharmacol 1987;27:78-83
   PubMed Web of Science ®Google Scholar
• Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984;9:511-44
   PubMed Web of Science ®Google Scholar
• Jain A, Mehta VL, Kulshrestha S. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis. Tuber Lung Dis 1993;74:87-90
   PubMedGoogle Scholar
• Weiner M, Burman W, Luo CC, et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 2007;51:2861-6
   PubMed Web of Science ®Google Scholar
• Nijland HM, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007;45:1001-7
   PubMed Web of Science ®Google Scholar
• McIlleron H, Norman J, Kanyok TP, et al. Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers. J Antimicrob Chemother 2007;60:1398-401
   PubMed Web of Science ®Google Scholar
• Acocella G, Bertrand A, Beytout J, et al. Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study. J Antimicrob Chemother 1989;23:433-9
   PubMed Web of Science ®Google Scholar
• Ruslami R, Nijland H, Aarnoutse R, et al. Evaluation of high-versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2006;50:822-3
   PubMed Web of Science ®Google Scholar
• Chan SL, Yew WW, Porter JHD, et al. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int J Antimicrob Agents 1994;3:267-74
   PubMedGoogle Scholar
• Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978;3:108-27
   PubMed Web of Science ®Google Scholar
• Tam CM, Chan SL, Lam CW, et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. Am J Respir Crit Care Med 1998;157:1726-33
   PubMed Web of Science ®Google Scholar
• Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002;360:528-34
   PubMed Web of Science ®Google Scholar
• Keung A, Reith K, Eller MG, et al. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I. Int J Tuberc Lung Dis 1999;3:426-36
   PubMed Web of Science ®Google Scholar
• Keung A, Eller MG, McKenzie KA, Weir SJ. Single and multiple dose pharmacokinetics of rifapentine in man: part II. Int J Tuberc Lung Dis 1999;3:437-44
   PubMed Web of Science ®Google Scholar
• Weiner M, Bock N, Peloquin CA, et al. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med 2004;169:1191-7
   PubMed Web of Science ®Google Scholar
• Heifets LB, Iseman MD. Determination of in vitro susceptibility of mycobacteria to ansamycin. Am Rev Respir Dis 1985;132:710-11
   PubMedGoogle Scholar
• Schwander S, Rusch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis 1995;76:210-18
   PubMedGoogle Scholar
• McGregor MM, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996;154:1462-7
   PubMed Web of Science ®Google Scholar
• Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001;164:7-12
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2000;49:185-9
   PubMedGoogle Scholar
• Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005;40:1481-91
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. 2008. Available from: http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm/ [Last accessed 3 June 2008]
   Google Scholar
• Narang PK, Lewis RC, Bianchine JR. Rifabutin absorption in humans: relative bioavailability and food effect. Clin Pharmacol Ther 1992;52:335-41
   PubMed Web of Science ®Google Scholar
• Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002;62:2169-83
   PubMed Web of Science ®Google Scholar
• Peloquin CA. Pharmacological issues in the treatment of tuberculosis. Ann NY Acad Sci 2001;953:157-64
   PubMed Web of Science ®Google Scholar
• Peloquin CA. Tuberculosis drug serum levels. Clin Infect Dis 2001;33:584-5
   PubMed Web of Science ®Google Scholar
• Boulanger C, Peloquin C, Hollender E, et al. PK analysis of rifabutin given with lopinavir/ritonavir to persons co-infected with TB and HIV [abstract]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia 22-25 July, 2007
   Google Scholar
• Heifets LB. Drug susceptibility tests in the management of chemotherapy of tuberculosis. In: Heifets LB, editor, Drug Susceptibility in the Chemotherapy of Mycobacterial Infections. Boca Raton, FL: CRC Press, 1991. p. 89-122
   Google Scholar
• Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001;61:9-18
   PubMed Web of Science ®Google Scholar
• Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against mycobacterium tuberculosis. Antimicrob Agents Chemother 2002;46:1022-5
   PubMed Web of Science ®Google Scholar
• Lounis N, Bentoucha A, Truffot-Pernot C, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001;45:3482-6
   PubMed Web of Science ®Google Scholar
• Rastogi N, Goh KS. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against mycobacterium tuberculosis compared with activities of olfoxacin and ciprofloxacin. Antimicrob Agents Chemother 1991;35:1933-36
   Google Scholar
• Garcia-Rodriguez JA, Gomez Garcia AC. In vitro activities of quinolones against mycobacteria. J Antimicrob Chemother 1993;32:797-808
   PubMed Web of Science ®Google Scholar
• Davis SL, Neuhauser MM, McKinnon PS. Quinolones. Second edition. In: Yu VL, Edwards G, McKinnon PS, et al., editors. Antimicrobial Chemotherapy and Vaccines. Vol. 2. Antimicrobial Agents. Pittsburgh, PA: ESun Technologies, 2005. p. 337-66
   Google Scholar
• Peloquin CA, Auclair B. Pharmacology of the second-line antituberculosis drugs. In: Portaels F, Bastian I, editors. Multidrug-resistant tuberculosis. Dordrecht, Netherlands: Kluwer Academic, 2000. p. 163-74
   Google Scholar
• Tsikouris JP, Peeters MJ, Cox CD, et al. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006;11:52-6
   PubMed Web of Science ®Google Scholar
• Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-61
   PubMed Web of Science ®Google Scholar
• Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007;41:1859-66
   PubMed Web of Science ®Google Scholar
• Sode J, Obel N, Hallas J, Lassen A. Use of fluroquinolone and risk of Achilles tendon rupture: a population-based cohort study. Eur J Clin Pharmacol 2007;63:499-503
   PubMed Web of Science ®Google Scholar
• Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004;169:421-6
   PubMed Web of Science ®Google Scholar
• Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992;36:548-51
   PubMed Web of Science ®Google Scholar
• Pletz MW, De Roux A, Roth A, et al. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004;48:780-2
   PubMed Web of Science ®Google Scholar
• Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;10:605-12
   PubMed Web of Science ®Google Scholar
• Tomioka H, Sato K, Kajitani H, et al. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 2000;44:283-6
   PubMed Web of Science ®Google Scholar
• Vacher S, Pellegrin JL, Leblanc F, et al. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin. J Antimicrob Chemother 1999;44:647-52
   PubMed Web of Science ®Google Scholar
• Chaisson RE, Efron A, Ram M, et al. A randomized, placebo-controlled trial of moxifloxacin versus ethambutol in the initial phase of tuberculosis therapy in Brazil [abstract L-736-A]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 17-20 Sept 2007
   Google Scholar
• Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-8
   PubMed Web of Science ®Google Scholar
• Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:128-38
   PubMed Web of Science ®Google Scholar
• British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. First report: results during chemotherapy. British Thoracic Association. Brit J Dis Chest 1981;75:141-53
   PubMedGoogle Scholar
• Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003;3:432-42
   PubMed Web of Science ®Google Scholar
• Grimaldo ER, Tupasi TE, Rivera AB, et al. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int J Tuberc Lung Dis 2001;5:546-50
   PubMed Web of Science ®Google Scholar
• von Gottberg A, Klugman KP, Cohen C, et al. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 2008;371:1108-13
   PubMed Web of Science ®Google Scholar
• Zvonar R. Gatifloxacin-induced dysglycemia. Am J Health Syst Pharm 2006;63:2087-92
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services/Food and Drug Administration. Determination that TEQUIN (Gatifloxacin) was withdrawn from sale for reasons of safety or effectiveness. Federal Register September 9, 2008:52357-8
   Google Scholar
• Rodriguez JC, Ruiz M, Lopez M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002;20:464-7
   PubMed Web of Science ®Google Scholar
• Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother 2003;51(Suppl 2):9-16
   PubMed Web of Science ®Google Scholar
• Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003;138:135-42
   PubMed Web of Science ®Google Scholar
• Wienkers LC, Wynalda MA, Feenstra KL, et al. In vitro metabolism of linezolid (PNU-100766): lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586. Abstract 11. Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: American Society for Microbiology, Washington DC, 1999. p. 3
   Google Scholar
• Antal EJ, Hendershot PE, Batts DH, et al. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol 2001;41:552-62
   PubMed Web of Science ®Google Scholar
• Ntziora F, Falagas ME. Linezolid for the treatment of patients with mycobacterial infections: a systematic review. Int J Tuberc Lung Dis 2007;11:606-11
   PubMed Web of Science ®Google Scholar
• Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008;178:1180-5
   PubMed Web of Science ®Google Scholar
• French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003;51(Suppl 2):45-53
   PubMed Web of Science ®Google Scholar
• Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005;56:180-5
   PubMed Web of Science ®Google Scholar
• von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) – a report of ten cases. J Infect 2006;52:92-6
   PubMed Web of Science ®Google Scholar
• Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006;58:701-4
   PubMed Web of Science ®Google Scholar
• Rastogi R, Sultana Y, Ali A, Aqil M. Particulate and vesicular drug carriers in the management of tuberculosis. Curr Drug Deliv 2006;3:121-8
   PubMedGoogle Scholar
• Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 2005;85:227-34
   PubMed Web of Science ®Google Scholar
• Pandey R, Sharma A, Zahoor A, et al. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003;52:981-6
   PubMed Web of Science ®Google Scholar
• Garcia-Contreras L, Fiegel J, Telko MJ, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother 2007;51:2830-6
   PubMed Web of Science ®Google Scholar
• Fiegel J, Garcia-Contreras L, Thomas M, et al. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm Res 2008;25:805-11
   PubMed Web of Science ®Google Scholar
• Namdar R, Peloquin C. Ethionamide. Second edition. In: Yu VL, Edwards G, McKinnon PS, et al., editors. Antimicrobial Chemotherapy and Vaccines. Vol. 2. Antimicrobial Agents. Pittsburgh, PA: ESun Technologies, 2005. p. 533-8
   Google Scholar
• Morlock GP, Metchock B, Sikes D, et al. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003;47:3799-805
   PubMed Web of Science ®Google Scholar
• Winder FG, Collins PB, Whelan D. Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG. J Gen Microbiol 1971;66:379-80
   PubMedGoogle Scholar
• Somner AR, Brace AA. Late results of treatment of chronic drug-resistant pulmonary tuberculosis. Brit Med J 1966;26:775-8
   Google Scholar
• Zhu M, Namdar R, Stambaugh JJ, et al. Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis (Edinb) 2002;82:91-6
   PubMed Web of Science ®Google Scholar
• Spigelman M, Gillespie S. Tuberculosis drug development pipeline: progress and hope. Lancet 2006;367:945-7
   PubMed Web of Science ®Google Scholar
• O'Brien RJ, Spigelman M. New drugs for tuberculosis: current status and future prospects. Clin Chest Med 2005;26:327-40,vii
   PubMed Web of Science ®Google Scholar
• Khasnobis S, Escuyer VE, Chatterjee D. Emerging therapeutic targets in tuberculosis: post-genomic era. Expert Opin Ther Targets 2002;6:21-40
   PubMedGoogle Scholar
• Biava M, Porretta GC, Deidda D, Pompei R. New trends in development of antimycobacterial compounds. Infect Disord Drug Targets 2006;6:159-72
   PubMedGoogle Scholar
• Tomioka H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr Pharm Design 2006;12:4047-70
   PubMed Web of Science ®Google Scholar
• Janin YL. Antituberculosis drugs: ten years of research. Bioorg Med Chem 2007;15:2479-513
   PubMed Web of Science ®Google Scholar
• Stop TB Partnership. New Technologies for Tuberculosis Control: A Framework for Their Adoption, Introduction and Implementation. Geneva: World Health Organization, 2007
   Google Scholar
• Casenghi M. Development of New Drugs for TB Chemotherapy: Analysis of the Current Drug Pipeline. Geneva: Medecins San Frontieres, Campaign for Access to Essential Medicines, 2006
   Google Scholar
• Hudson A, Imamura T, Gutteridge W, et al. The Current Anti-TB Drug Research and Development Pipeline. Geneva: Special Programme for Research and Training in Tropical Diseases, World Health Organization, 2003
   Google Scholar
• Tomioka H, Tatano Y, Yasumoto K, Shimizu T. Recent advances in antituberculous drug development and novel drug targets. Expert Rev Respir Med 2008;2:455-71
   PubMedGoogle Scholar
• Glickman SW, Rasiel EB, Hamilton CD, et al. Medicine. A portfolio model of drug development for tuberculosis. Science (NY) 2006;311:1246-7
   PubMed Web of Science ®Google Scholar
• Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science (NY) 2005;307:223-7
   PubMed Web of Science ®Google Scholar
• Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:2831-5
   PubMed Web of Science ®Google Scholar
• Veziris N, Ibrahim M, Lounis N, et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med 2009;179(1):75-9
   Google Scholar
• Ibrahim M, Truffot-Pernot C, Andries K, et al. Early and late bactericidal activity of R207910 (TMC207) in murine tuberculosis. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting. Washington DC, USA, October 25-28, 2008
   Google Scholar
• Diacon AH, Pym A, Grobusch M, et al. Interim analysis of a double-blind, placebo-controlled study with TMC207 in patients with multi-drug resistant (MDR) tuberculosis. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting. Washington DC, October 25-28, 2008
   Google Scholar
• Ibrahim M, Truffot-Pernot C, Andries K, et al. Sterilizing activity of a second line regimen including R207910 (TMC207) in murine tuberculosis. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting. Washington DC, October 25-28, 2008
   Google Scholar
• Stover KC, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000;405:962-6
   PubMed Web of Science ®Google Scholar
• Pa-824. Tuberculosis (Edinb) 2008;88:134-6
   PubMedGoogle Scholar
• Lenaerts AJ, Gruppo V, Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005;49:2294-301
   PubMed Web of Science ®Google Scholar
• Ginsberg A, Diacon A, Dawson R, et al. Extended early bactericidal activity (EBA) of PA-824, a novel drug for tuberculosis treatment. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting. Washington DC, October 25-28, 2008
   Google Scholar
• Nuermberger E, Rosenthal I, Tyagi S, et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2006;50:2621-5
   PubMed Web of Science ®Google Scholar
• Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008;52:1522-4
   PubMed Web of Science ®Google Scholar
• Doi N, Disratthakit A. Characterization of in vivo activity of novel anti-TB drug candidates OPC-67683 and PA-824 in murine TB models. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting. Washington DC, October 25-28, 2008
   Google Scholar
• Laurenzi M. Nitroimidazo-oxazine PA-824. The Second Annual Open Forum on Key Issues in TB Drug Development. London, UK, 12-13 Dec 2006
   Google Scholar
• Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;3:e466
   PubMed Web of Science ®Google Scholar
• Hittel N. Nitroduhydro-imidazooxazole derivative OPC-67683. The Second Annual Open Forum on Key Issues in TB Drug Development. London, UK, 2006
   Google Scholar
• Biava M, Porretta GC, Poce G, et al. Antimycobacterial agents. Novel diarylpyrrole derivatives of BM212 endowed with high activity toward Mycobacterium tuberculosis and low cytotoxicity. J Med Chem 2006;49:4946-52
   PubMed Web of Science ®Google Scholar
• Jia L, Noker PE, Coward L, et al. Interspecies pharmacokinetics and in vitro metabolism of SQ109. Brit J Pharmacol 2006;147:476-85
   PubMed Web of Science ®Google Scholar
• Chen P, Gearhart J, Protopopova M, et al. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 2006;58:332-7
   PubMed Web of Science ®Google Scholar
• Nikonenko BV, Protopopova M, Samala R, et al. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 2007;51:1563-5
   PubMed Web of Science ®Google Scholar
• Reddy VM, Einck L, Andries K, Nacy CA. The new antitubercular drugs SQ109 and TMC207 act synergistically in vitro to kill M. tuberculosis. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting. Washington DC, October 25-28, 2008
   Google Scholar
• Nacy C. Diamine SQ109. The Second Annual Open Forum on Key Issues in TB Drug Development. London, UK, 2006
   Google Scholar